دورية أكاديمية
أعرض في EDS

The Immune Response of OAS1 , IRF9 , and IFI6 Genes in the Pathogenesis of COVID-19.

التفاصيل البيبلوغرافية
العنوان: The Immune Response of OAS1 , IRF9 , and IFI6 Genes in the Pathogenesis of COVID-19.
المؤلفون: Gajate-Arenas M; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain., Fricke-Galindo I; HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico., García-Pérez O; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain., Domínguez-de-Barros A; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain., Pérez-Rubio G; HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico., Dorta-Guerra R; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain.; Department of Mathematics, Statistics and Operations Research, Faculty of Sciences, Mathematics Section, Universidad de La Laguna, 38200 San Cristóbal de La Laguna, Spain., Buendía-Roldán I; Translational Research Laboratory on Aging and Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico., Chávez-Galán L; Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City 14080, Mexico., Lorenzo-Morales J; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.; Department of Obstetrics and Gynecology, Pediatrics, Preventive Medicine and Public Health, Toxicology, Legal and Forensic Medicine and Parasitology, Faculty of Health Sciences, Universidad de La Laguna, 38200 San Cristóbal de La Laguna, Spain., Falfán-Valencia R; HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico., Córdoba-Lanús E; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, 38029 San Cristóbal de La Laguna, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 24; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: 2',5'-Oligoadenylate Synthetase*/genetics , COVID-19*/genetics , COVID-19*/immunology , COVID-19*/virology , SARS-CoV-2* , Interferon-Stimulated Gene Factor 3, gamma Subunit*/genetics , Interferon-Stimulated Gene Factor 3, gamma Subunit*/metabolism, Humans ; Male ; Female ; Middle Aged ; Nuclear Proteins/genetics ; Adult ; Aged ; Mitochondrial Proteins
مستخلص: COVID-19 is characterized by a wide range of clinical manifestations, where aging, underlying diseases, and genetic background are related to worse outcomes. In the present study, the differential expression of seven genes related to immunity, IRF9 , CCL5 , IFI6 , TGFB1 , IL1B , OAS1 , and TFRC , was analyzed in individuals with COVID-19 diagnoses of different disease severities. Two-step RT-qPCR was performed to determine the relative gene expression in whole-blood samples from 160 individuals. The expression of OAS1 ( p < 0.05) and IFI6 ( p < 0.05) was higher in moderate hospitalized cases than in severe ones. Increased gene expression of OAS1 (OR = 0.64, CI = 0.52-0.79; p = 0.001), IRF9 (OR = 0.581, CI = 0.43-0.79; p = 0.001), and IFI6 (OR = 0.544, CI = 0.39-0.69; p < 0.001) was associated with a lower risk of requiring IMV. Moreover, TGFB1 (OR = 0.646, CI = 0.50-0.83; p = 0.001), CCL5 (OR = 0.57, CI = 0.39-0.83; p = 0.003), IRF9 (OR = 0.80, CI = 0.653-0.979; p = 0.03), and IFI6 (OR = 0.827, CI = 0.69-0.991; p = 0.039) expression was associated with patient survival. In conclusion, the relevance of OAS1 , IRF9 , and IFI6 in controlling the viral infection was confirmed.
References: Genomics Inform. 2013 Mar;11(1):15-23. (PMID: 23613678)
Cell. 2020 Jun 11;181(6):1194-1199. (PMID: 32405102)
mBio. 2014 May 20;5(3):e01174-14. (PMID: 24846384)
Nat Med. 2021 Apr;27(4):659-667. (PMID: 33633408)
Biochem Biophys Res Commun. 2022 Nov 26;631:138-145. (PMID: 36183555)
Cell Rep Med. 2022 Jun 21;3(6):100663. (PMID: 35732153)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Front Cell Dev Biol. 2021 Jan 11;8:627302. (PMID: 33505977)
J Transl Autoimmun. 2021;4:100083. (PMID: 33521616)
medRxiv. 2020 May 05;:. (PMID: 32511656)
Viruses. 2022 Jun 21;14(7):. (PMID: 35891331)
JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899)
Int J Mol Sci. 2021 Dec 24;23(1):. (PMID: 35008594)
J Med Virol. 2021 Mar;93(3):1343-1350. (PMID: 33085084)
Sci Adv. 2021 Aug 18;7(34):. (PMID: 34407940)
Nat Rev Microbiol. 2021 Nov;19(11):685-700. (PMID: 34535791)
Int J Mol Sci. 2023 Jul 27;24(15):. (PMID: 37569398)
Nat Commun. 2020 Jun 11;11(1):2953. (PMID: 32528005)
Int J Biol Sci. 2022 Jan 1;18(2):459-472. (PMID: 35002503)
J Interferon Cytokine Res. 2011 Jan;31(1):41-7. (PMID: 21142819)
Front Immunol. 2020 Jun 16;11:1446. (PMID: 32612617)
Heliyon. 2020 Oct;6(10):e05143. (PMID: 33024851)
Front Immunol. 2023 Aug 08;14:1233318. (PMID: 37614228)
Expert Rev Clin Pharmacol. 2021 May;14(5):601-621. (PMID: 33705239)
Nat Genet. 2022 Aug;54(8):1103-1116. (PMID: 35835913)
Front Immunol. 2022 Jan 05;12:806400. (PMID: 35069589)
J Med Virol. 2023 Jul;95(7):e28894. (PMID: 37386895)
Int J Infect Dis. 2023 Sep;134:126-132. (PMID: 37290572)
J Leukoc Biol. 2021 Dec;110(6):1225-1239. (PMID: 34730254)
Nat Nanotechnol. 2020 Aug;15(8):630-645. (PMID: 32661375)
J Glob Health. 2020 Dec;10(2):020503. (PMID: 33110586)
J Chin Med Assoc. 2021 Jan 1;84(1):3-8. (PMID: 33230062)
PLoS Biol. 2020 Sep 8;18(9):e3000849. (PMID: 32898168)
J Allergy Clin Immunol. 2022 Oct;150(4):955-964.e16. (PMID: 35182547)
Nat Commun. 2020 Nov 17;11(1):5854. (PMID: 33203890)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Front Mol Biosci. 2022 Mar 16;9:756895. (PMID: 35372510)
Expert Opin Ther Targets. 2013 Dec;17(12):1439-60. (PMID: 24090198)
J Infect. 2020 Jun;80(6):607-613. (PMID: 32283152)
J Allergy Clin Immunol. 2019 Jul;144(1):309-312.e10. (PMID: 30826365)
Front Med (Lausanne). 2022 Oct 21;9:1000147. (PMID: 36341268)
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4. (PMID: 8421714)
Front Cell Infect Microbiol. 2023 Jun 14;13:1173213. (PMID: 37389217)
Sci Rep. 2023 Apr 19;13(1):6415. (PMID: 37076543)
J Clin Med. 2020 Nov 21;9(11):. (PMID: 33233425)
J Infect Dis. 2022 Mar 15;225(6):977-982. (PMID: 34910814)
Front Immunol. 2021 Apr 01;12:622176. (PMID: 33868239)
Heliyon. 2020 Dec;6(12):e05684. (PMID: 33344791)
Br J Cancer. 2018 Jul;119(1):52-64. (PMID: 29899394)
Science. 2021 Oct 29;374(6567):eabj3624. (PMID: 34581622)
Hum Gene (Amst). 2023 Feb;35:201135. (PMID: 37521006)
Front Immunol. 2022 Aug 08;13:940756. (PMID: 36003396)
Annu Rev Immunol. 2006;24:99-146. (PMID: 16551245)
Front Immunol. 2023 May 24;14:1146704. (PMID: 37292210)
Annu Rev Immunol. 2014;32:513-45. (PMID: 24555472)
Cell Host Microbe. 2009 Sep 17;6(3):207-17. (PMID: 19664979)
Sci Rep. 2015 Mar 11;5:9012. (PMID: 25757571)
معلومات مُعتمدة: CIBERINFEC CB21/13/00100 Centro de Investigación Biomédica en Red; 2023-2028; PI-CC202302222, Cabildo.23 Cabildo de Tenerife; Spain Ministry of Health
فهرسة مساهمة: Keywords: COVID-19; SARS-CoV-2; antiviral genes; gene expression; immune response
المشرفين على المادة: EC 2.7.7.84 (2',5'-Oligoadenylate Synthetase)
EC 2.7.7.- (OAS1 protein, human)
0 (IFI6 protein, human)
0 (Interferon-Stimulated Gene Factor 3, gamma Subunit)
0 (IRF9 protein, human)
0 (Nuclear Proteins)
0 (Mitochondrial Proteins)
تواريخ الأحداث: Date Created: 20240511 Date Completed: 20240511 Latest Revision: 20240530
رمز التحديث: 20240531
مُعرف محوري في PubMed: PMC11083791
DOI: 10.3390/ijms25094632
PMID: 38731851
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25094632